{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T12:31:21Z","timestamp":1788093081462,"version":"build-2803163510"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2023,4,15]],"date-time":"2023-04-15T00:00:00Z","timestamp":1681516800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,4,15]],"date-time":"2023-04-15T00:00:00Z","timestamp":1681516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"DOI":"10.1007\/s10238-023-01071-8","type":"journal-article","created":{"date-parts":[[2023,4,15]],"date-time":"2023-04-15T11:02:02Z","timestamp":1681556522000},"page":"3947-3955","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Pulmonary large cell neuroendocrine carcinoma (LCNEC): a population-based study addressing recent molecular-genetic advances and emerging therapeutic approaches"],"prefix":"10.1007","volume":"23","author":[{"given":"Jaffar","family":"Khan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdul Qahar Khan","family":"Yasinzai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Matosz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjan","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saleh","family":"Heneidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hector","family":"Mesa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aman","family":"Chauhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaydira","family":"Del Rivero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nagla Abdel","family":"Karim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asad","family":"Ullah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,15]]},"reference":[{"issue":"6","key":"1071_CR1","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1097\/00000478-199106000-00003","volume":"15","author":"WD Travis","year":"1991","unstructured":"Travis WD, Linnoila RI, Tsokos MG, Hitchcock CL, Cutler GB Jr, Nieman L, et al. Neuroendocrine tumors of the lung with proposed criteria for large-cell neuroendocrine carcinoma. An ultrastructural, immunohistochemical, and flow cytometric study of 35 cases. Am J Surg Pathol. 1991;15(6):529\u201353.","journal-title":"Am J Surg Pathol"},{"key":"1071_CR2","doi-asserted-by":"publisher","first-page":"653162","DOI":"10.3389\/fonc.2021.653162","volume":"11","author":"V Corbett","year":"2021","unstructured":"Corbett V, Arnold S, Anthony L, Chauhan A. Management of large cell neuroendocrine carcinoma. Front Oncol. 2021;11:653162. https:\/\/doi.org\/10.3389\/fonc.2021.653162.","journal-title":"Front Oncol"},{"issue":"9","key":"1071_CR3","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1097\/JTO.0000000000000630","volume":"10","author":"WD Travis","year":"2015","unstructured":"Travis WD, Brambilla E, Nicholson AG, Yatabe Y, Austin JHM, Beasley MB, et al. The 2015 world health organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol. 2015;10(9):1243\u201360.","journal-title":"J Thorac Oncol"},{"issue":"3","key":"1071_CR4","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1053\/j.semtcvs.2006.08.007","volume":"18","author":"FG Fernandez","year":"2006","unstructured":"Fernandez FG, Battafarano RJ. Large-cell neuroendocrine carcinoma of the lung: an aggressive neuroendocrine lung cancer. Semin Thorac Cardiovasc Surg. 2006;18(3):206\u201310.","journal-title":"Semin Thorac Cardiovasc Surg"},{"issue":"5","key":"1071_CR5","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1016\/j.athoracsur.2006.05.109","volume":"82","author":"A Iyoda","year":"2006","unstructured":"Iyoda A, Hiroshima K, Moriya Y, Takiguchi Y, Sekine Y, Shibuya K, Iizasa T, Kimura H, Nakatani Y, Fujisawa T. Prospective study of adjuvant chemotherapy for pulmonary large cell neuroendocrine carcinoma. Ann Thorac Surg. 2006;82(5):1802\u20137. https:\/\/doi.org\/10.1016\/j.athoracsur.2006.05.109.","journal-title":"Ann Thorac Surg"},{"key":"1071_CR6","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1001\/jama.2019.11058","volume":"322","author":"KC Arbour","year":"2019","unstructured":"Arbour KC, Riely GJ. Systemic therapy for locally advanced and metastatic non-small cell lung cancer: a review. JAMA. 2019;322:764\u201374.","journal-title":"JAMA"},{"issue":"1","key":"1071_CR7","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1200\/JCO.2005.04.1202","volume":"24","author":"H Asamura","year":"2006","unstructured":"Asamura H, Kameya T, Matsuno Y, Noguchi M, Tada H, Ishikawa Y, et al. Neuroendocrine neoplasms of the lung: a prognostic spectrum. J Clin Oncol. 2006;24(1):70\u20136.","journal-title":"J Clin Oncol"},{"key":"1071_CR8","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1097\/JTO.0000000000000589","volume":"10","author":"M Fasano","year":"2015","unstructured":"Fasano M, della Corte CM, Papaccio F, Ciardiello F, Morgillo F. Pulmonary large-cell neuroendocrine carcinoma from epidemiology to therapy. J Thorac Oncol. 2015;10:1133\u201341. https:\/\/doi.org\/10.1097\/JTO.0000000000000589.","journal-title":"J Thorac Oncol"},{"key":"1071_CR9","unstructured":"Travis WDBE, Burke AP, Marx A, Nicholson AGL. WHO classification of tumours of the lung, pleura, thymus and heart (medicine), 4th edn. WHO Classification of Tumours Editorial Board: World Health Organization; 2015."},{"issue":"6","key":"1071_CR10","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1093\/annonc\/mdt009","volume":"24","author":"J Le Treut","year":"2013","unstructured":"Le Treut J, et al. Multicentre phase II study of cisplatin\u2013etoposide chemotherapy for advanced large-cell neuroendocrine lung carcinoma: the GFPC 0302 study. Ann Oncol. 2013;24(6):1548\u201352.","journal-title":"Ann Oncol"},{"key":"1071_CR11","doi-asserted-by":"publisher","first-page":"572462","DOI":"10.3389\/fonc.2020.572462","volume":"10","author":"L Zou","year":"2020","unstructured":"Zou L, Guo T, Ye L, Zhou Y, Chu L, Chu X, et al. Outcomes for surgery in stage IA large cell lung neuroendocrine compared with other types of non-small cell lung cancer: a propensity score matching study based on the surveillance, epidemiology, and end results (SEER) database. Front Oncol. 2020;10:572462.","journal-title":"Front Oncol"},{"issue":"2","key":"1071_CR12","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1183\/13993003.00618-2015","volume":"47","author":"JL Derks","year":"2016","unstructured":"Derks JL, Hendriks LE, Buikhuisen WA, Groen HJ, Thunnissen E, van Suylen RJ, et al. Clinical features of large cell neuroendocrine carcinoma: a population-based overview. Eur Respir J. 2016;47(2):615\u201324.","journal-title":"Eur Respir J"},{"issue":"3","key":"1071_CR13","doi-asserted-by":"publisher","first-page":"245","DOI":"10.4143\/crt.2003.35.3.245","volume":"35","author":"MS Park","year":"2003","unstructured":"Park MS, Kim KD, Chung JH, Shin DH, Chung KY, Kim JH, et al. Clinical features of pulmonary large cell neuroendocrine carcinoma. Cancer Res Treat. 2003;35(3):245\u201353.","journal-title":"Cancer Res Treat"},{"issue":"2","key":"1071_CR14","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/S0003-4975(02)04118-8","volume":"75","author":"J Zacharias","year":"2003","unstructured":"Zacharias J, Nicholson AG, Ladas GP, Goldstraw P. Large cell neuroendocrine carcinoma and large cell carcinomas with neuroendocrine morphology of the lung: prognosis after complete resection and systematic nodal dissection. Ann Thorac Surg. 2003;75(2):348\u201352.","journal-title":"Ann Thorac Surg"},{"issue":"5","key":"1071_CR15","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.jtho.2018.01.019","volume":"13","author":"L Kujtan","year":"2018","unstructured":"Kujtan L, Muthukumar V, Kennedy KF, Davis JR, Masood A, Subramanian J. The role of systemic therapy in the management of stage I large cell neuroendocrine carcinoma of the lung. J Thorac Oncol. 2018;13(5):707\u201314.","journal-title":"J Thorac Oncol"},{"issue":"36","key":"1071_CR16","doi-asserted-by":"publisher","first-page":"4292","DOI":"10.1200\/JCO.20.01806","volume":"38","author":"H Kenmotsu","year":"2020","unstructured":"Kenmotsu H, Niho S, Tsuboi M, Wakabayashi M, Ishii G, Nakagawa K, et al. Randomized phase III study of irinotecan plus cisplatin versus etoposide plus cisplatin for completely resected high-grade neuroendocrine carcinoma of the lung: JCOG1205\/1206. J Clin Oncol. 2020;38(36):4292\u2013301.","journal-title":"J Clin Oncol"},{"issue":"25","key":"1071_CR17","doi-asserted-by":"publisher","first-page":"6422","DOI":"10.7150\/jca.32446","volume":"10","author":"Y Jiang","year":"2019","unstructured":"Jiang Y, Lei C, Zhang X, Cui Y, Che K, Shen H. Double-edged role of radiotherapy in patients with pulmonary large-cell neuroendocrine carcinoma. J Cancer. 2019;10(25):6422\u201330.","journal-title":"J Cancer"},{"issue":"6","key":"1071_CR18","doi-asserted-by":"publisher","first-page":"2979","DOI":"10.1002\/cam4.2188","volume":"8","author":"J Gu","year":"2019","unstructured":"Gu J, Gong D, Wang Y, Chi B, Zhang J, Hu S, et al. The demographic and treatment options for patients with large cell neuroendocrine carcinoma of the lung. Cancer Med. 2019;8(6):2979\u201393.","journal-title":"Cancer Med"},{"key":"1071_CR19","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1200\/JCO.2005.04.8595","volume":"24","author":"HN Bunn Jr","year":"2006","unstructured":"Bunn HN Jr, Langer PA, et al. Randomized phase III trial comparing irinotecan\/cisplatin with etoposide\/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol. 2006;24:2038\u201343. https:\/\/doi.org\/10.1200\/JCO.2005.04.8595.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1071_CR20","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1158\/1078-0432.CCR-17-1921","volume":"24","author":"JL Derks","year":"2018","unstructured":"Derks JL, Leblay N, Thunnissen E, van Suylen RJ, den Bakker M, Groen HJM, Smit EF, Damhuis R, van den Broek EC, Charbrier A, Foll M, McKay JD, Fernandez-Cuesta L, Speel E-JM, Dingemans A-MC, PALGA-Group. Molecular subtypes of pulmonary large-cell neuroendocrine carcinoma predict chemotherapy treatment outcome. Clin Cancer Res. 2018;24(1):33\u201342. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-1921.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"1071_CR21","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1158\/1078-0432.CCR-19-0556","volume":"26","author":"M Zhuo","year":"2020","unstructured":"Zhuo M, Guan Y, Yang X, Hong L, Wang Y, Li Z, Chen R, Abbas HA, Chang L, Gong Y, Wu N, Zhong J, Chen W, Chen H, Dong Z, Zhu X, Li J, Wang Y, An T, Wu M, Wang Z, Wang J, Roarty EB, Rinsurongkawong W, Lewis J, Roth JA, Swisher SG, Lee JJ, Heymach JV, Wistuba II, Kalhor N, Yang L, Yi X, Futreal PA, Glisson BS, Xia X, Zhang J, Zhao J. The prognostic and therapeutic role of genomic subtyping by sequencing tumor or cell-free DNA in pulmonary large-cell neuroendocrine carcinoma. Clin Cancer Res. 2020;26(4):892\u2013901. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-0556.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"1071_CR22","doi-asserted-by":"publisher","first-page":"2290","DOI":"10.1158\/1078-0432.CCR-19-3356","volume":"26","author":"SP Patel","year":"2020","unstructured":"Patel SP, Othus M, Chae YK, Giles FJ, Hansel DE, Singh PP, Fontaine A, Shah MH, Kasi A, Baghdadi TA, Matrana M, Gatalica Z, Korn WM, Hayward J, McLeod C, Chen HX, Sharon E, Mayerson E, Ryan CW, Plets M, Blanke CD, Kurzrock R. A phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART SWOG 1609) in patients with nonpancreatic neuroendocrine tumors. Clin Cancer Res. 2020;26(10):2290\u20136. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-3356.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1071_CR23","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/ejcts\/ezs174","volume":"43","author":"L Fournel","year":"2013","unstructured":"Fournel L, Falcoz PE, Alifano M, Charpentier MC, Boudaya MS, Magdeleinat P, et al. Surgical management of pulmonary large cell neuroendocrine carcinomas: a 10-year experience. Eur J Cardiothorac Surg. 2013;43(1):111\u20134.","journal-title":"Eur J Cardiothorac Surg"},{"issue":"1","key":"1071_CR24","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1097\/CAD.0b013e328330fd79","volume":"21","author":"H Saji","year":"2010","unstructured":"Saji H, Tsuboi M, Matsubayashi J, Miyajima K, Shimada Y, Imai K, et al. Clinical response of large cell neuroendocrine carcinoma of the lung to perioperative adjuvant chemotherapy. Anticancer Drugs. 2010;21(1):89\u201393.","journal-title":"Anticancer Drugs"},{"key":"1071_CR25","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1158\/1078-0432.CCR-19-0556","volume":"26","author":"M Zhuo","year":"2020","unstructured":"Zhuo M, Guan Y, Yang X, Hong L, Wang Y, Li Z, et al. The prognostic and therapeutic role of genomic subtyping by sequencing tumor or cell-free DNA in pulmonary large-cell neuroendocrine carcinoma. Clin Cancer Res. 2020;26:892\u2013901.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1071_CR26","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1038\/s41467-018-03099-x","volume":"9","author":"J George","year":"2018","unstructured":"George J, Walter V, Peifer M, Alexandrov LB, Seidel D, Leenders F, et al. Integrative genomic profiling of large-cell neuroendocrine carcinomas reveals distinct subtypes of high-grade neuroendocrine lung tumors. Nat Commun. 2018;9(1):1048.","journal-title":"Nat Commun"},{"issue":"1","key":"1071_CR27","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1158\/1078-0432.CCR-17-1921","volume":"24","author":"JL Derks","year":"2018","unstructured":"Derks JL, Leblay N, Thunnissen E, Van Suylen RJ, Den Bakker M, Groen HJM, et al. Molecular subtypes of pulmonary large-cell neuroendocrine carcinoma predict chemotherapy treatment outcome. Clin Cancer Res. 2018;24(1):33\u201342.","journal-title":"Clin Cancer Res"},{"key":"1071_CR28","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.lungcan.2019.02.022","volume":"130","author":"BCM Hermans","year":"2019","unstructured":"Hermans BCM, Derks JL, Thunnissen E, van Suylen RJ, den Bakker MA, Groen HJM, et al. Prevalence and prognostic value of PD-L1 expression in molecular subtypes of metastatic large cell neuroendocrine carcinoma (LCNEC). Lung Cancer. 2019;130:179\u201386.","journal-title":"Lung Cancer"},{"issue":"15_suppl","key":"1071_CR29","doi-asserted-by":"publisher","first-page":"8535","DOI":"10.1200\/JCO.2021.39.15_suppl.8535","volume":"39","author":"C Kim","year":"2021","unstructured":"Kim C, McGrath JE, Xiu J, Nagasaka M, Ma PC, Nieva JJ, et al. Genomic and immunologic characterization of large-cell neuroendocrine carcinoma of the lung. J Clin Oncol. 2021;39(15_suppl):8535.","journal-title":"J Clin Oncol"},{"key":"1071_CR30","doi-asserted-by":"publisher","first-page":"650293","DOI":"10.3389\/fonc.2021.650293","volume":"11","author":"MG Ferrara","year":"2021","unstructured":"Ferrara MG, Stefani A, Simbolo M, Pilotto S, Martini M, Lococo F, et al. Large cell neuro-endocrine carcinoma of the lung: current treatment options and potential future opportunities. Front Oncol. 2021;11:650293.","journal-title":"Front Oncol"},{"key":"1071_CR31","doi-asserted-by":"publisher","first-page":"667468","DOI":"10.3389\/fonc.2021.667468","volume":"11","author":"T Atieh","year":"2021","unstructured":"Atieh T, Huang CH. Treatment of advanced-stage large cell neuroendocrine cancer (LCNEC) of the lung: a tale of two diseases. Front Oncol. 2021;11:667468.","journal-title":"Front Oncol"},{"key":"1071_CR32","doi-asserted-by":"publisher","first-page":"655752","DOI":"10.3389\/fonc.2021.655752","volume":"11","author":"H Popper","year":"2021","unstructured":"Popper H, Brcic L. Diagnosis and molecular profiles of large cell neuroendocrine carcinoma with potential targets for therapy. Front Oncol. 2021;11:655752.","journal-title":"Front Oncol"},{"issue":"1","key":"1071_CR33","doi-asserted-by":"publisher","first-page":"71","DOI":"10.21037\/tlcr-20-374","volume":"10","author":"MS May","year":"2021","unstructured":"May MS, Kinslow CJ, Adams C, Saqi A, Shu CA, Chaudhary KR, Wang TJC, Cheng SK. Outcomes for localized treatment of large cell neuroendocrine carcinoma of the lung in the United States. Transl Lung Cancer Res. 2021;10(1):71\u20139. https:\/\/doi.org\/10.21037\/tlcr-20-374.","journal-title":"Transl Lung Cancer Res"},{"issue":"23","key":"1071_CR34","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","volume":"379","author":"L Horn","year":"2018","unstructured":"Horn L, Mansfield AS, Szcz\u0119sna A, Havel L, Krzakowski M, Hochmair MJ, Huemer F, Losonczy G, Johnson ML, Nishio M, Reck M, Mok T, Lam S, Shames DS, Liu J, Ding B, Lopez-Chavez A, Kabbinavar F, Lin W, Sandler A, Liu SV, IMpower133 Study Group. First-line Atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med. 2018;379(23):2220\u20139. https:\/\/doi.org\/10.1056\/NEJMoa1809064.","journal-title":"N Engl J Med"},{"issue":"1","key":"1071_CR35","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S1470-2045(20)30539-8","volume":"22","author":"JW Goldman","year":"2021","unstructured":"Goldman JW, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, Statsenko G, Hochmair MJ, \u00d6zg\u00fcro\u011flu M, Ji JH, Garassino MC, Voitko O, Poltoratskiy A, Ponce S, Verderame F, Havel L, Bondarenko I, Ka\u017carnowicz A, Losonczy G, Conev NV, Armstrong J, Byrne N, Thiyagarajah P, Jiang H, Paz-Ares L, CASPIAN Investigators. Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2021;22(1):51\u201365. https:\/\/doi.org\/10.1016\/S1470-2045(20)30539-8.","journal-title":"Lancet Oncol"},{"key":"1071_CR36","doi-asserted-by":"publisher","first-page":"3488","DOI":"10.1200\/JCO.2015.62.1342","volume":"33","author":"GA Masters","year":"2015","unstructured":"Masters GA, Temin S, Azzoli CG, et al. Systemic therapy for stage IV non-small-cell lung cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2015;33:3488\u2013515.","journal-title":"J Clin Oncol"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-023-01071-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-023-01071-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-023-01071-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T20:12:14Z","timestamp":1698783134000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-023-01071-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,15]]},"references-count":36,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,11]]}},"alternative-id":["1071"],"URL":"https:\/\/doi.org\/10.1007\/s10238-023-01071-8","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,15]]},"assertion":[{"value":"7 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Patient consent was waived due to this article being from SEER database, which are publicly available deidentified patients\u2019 data from National Cancer Institute (NCI), USA.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}